Company profile: Medac Pharma
1.1 - Company Overview
Company description
- Provider of healthcare products for rare diseases across rheumatology, auto-immune conditions, pediatrics, and specialty oncology. Offers therapies such as methotrexate formulations (Rasuvo auto-injector, Metoject pre-filled syringe) for rheumatoid arthritis and other auto-immune diseases; Rupall for allergies; IXINITY for Hemophilia B; Gleolan for glioma imaging; Trecondyv for transplant conditioning.
Products and services
- Rasuvo: Methotrexate auto-injector that delivers treatment for rheumatoid arthritis and other auto-immune diseases in an injection device format, auto-injector-based
- Metoject: Pre-filled syringe formulation of methotrexate for rheumatoid arthritis and auto-immune diseases treatment, pre-filled dosing format
- IXINITY: Used for the control and prevention of bleeding episodes in patients with Hemophilia B, Hemophilia B–specific
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Medac Pharma
Sitryx
HQ: United Kingdom
Website
- Description: Provider of cell metabolism–targeted, first-in-class, disease-modifying therapeutics in immuno-oncology and immuno-inflammation. Pipeline includes SYX-5219 for atopic dermatitis; SIT-052, an inhaled GLS1 inhibitor for pulmonary fibrosis and COPD that selectively breaks down senescent cells; SIT-033, a SIK2 inhibitor for ulcerative colitis; and SYX-1042 and SIT-047 for autoimmune indications (with Eli Lilly).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sitryx company profile →
Gesynta Pharma
HQ: Sweden
Website
- Description: Provider of clinical-stage pharmaceutical R&D developing mPGES-1–inhibiting drug candidates to reduce inflammation and pain. Pipeline includes vipoglanstat (GS-248), a non-hormonal treatment for endometriosis in phase II, and GS-073 for chronic inflammatory pain entering phase I. Research originates from Karolinska Institutet; GS-073 from AstraZeneca.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gesynta Pharma company profile →
Mount Tam Biotech
HQ: United States
Website
- Description: Provider of services to develop, optimize, and bring to market novel pharmaceuticals.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mount Tam Biotech company profile →
AB2 Bio
HQ: Switzerland
Website
- Description: Provider of drug discovery and development of best-in-class therapies for inflammatory diseases, including Tadekinig alfa, a recombinant IL-18 binding protein restoring the IL-18/IL-18BP balance; a proprietary assay to detect and measure free IL-18; and clinical programs in primary HLH (Phase III), secondary HLH/MAS, and adult-onset Still's disease (Phase II).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AB2 Bio company profile →
Pandion Therapeutics
HQ: United States
Website
- Description: Provider of bispecific antibody therapeutics, modular proteins, and antibodies for localized immunomodulation at the site of disease, enabling durable, tissue-specific treatment for patients with autoimmune and inflammatory diseases and organ transplants.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pandion Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Medac Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Medac Pharma
2.2 - Growth funds investing in similar companies to Medac Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Medac Pharma
4.2 - Public trading comparable groups for Medac Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →